BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 1.02.2019

Immunogenicity Testing of Therapeutic Protein Products-Developing and Validating Assays for Anti-Drug Antibody Detection; Guidance for Industry; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Immunogenicity Testing of Therapeutic Protein Products--Developing and Validating Assays for Anti-Drug Antibody Detection." This guidance provides recommendations to facilitate industry's development and validation of assays for assessment of the immunogenicity of therapeutic protein products during clinical trials. The guidance applies to assays for the detection of anti-drug antibodies (ADAs) and may also apply to some peptides, oligonucleotides, and combination products on a case-by-case basis. The guidance includes recommendations regarding the development and validation of screening assays, confirmatory assays, titration assays, and neutralization assays. This guidance finalizes the revised draft guidance for industry entitled "Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products" issued in April 2016 and includes a revised title.

Source: Federal Register — Food and Drug AdministrationOpen original release →